Tumor necrosis factor (TNF)-α-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors

被引:29
作者
Frishman, JI
Edwards, CK
Sonnenberg, MG
Kohno, T
Cohen, AM
Dinarello, CA
机构
[1] Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Dept Med, Denver, CO 80262 USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
D O I
10.1086/317605
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The dose-dependent increase in mortality in patients with sepsis who are treated with tumor necrosis factor (TNF) p75 soluble receptor Fc conjugate (p75-Fc) remains unexplained. In this study, neutralization of TNF-alpha -induced interleukin (IL)-8 by p75-Fc in whale human blood exhibited a U-shaped inhibition curve, whereas the TNF-soluble p55 receptor, linked to polyethylene glycol (p55-PEG), exhibited a dose-dependent inhibition. Native soluble p75 increased TNF-alpha -induced IL-8, versus a 61% reduction by native p55, Spontaneous IL-8 production was increased by p75-Fe or native p75 but not by p55-PEG or native p55, Unexpectedly, TNF-alpha -stimulated IL-1 receptor antagonist was suppressed by p75-Fc but not by p55-PEG, Studies of binding to TNF trimer revealed that p75-Fe has an affinity 40-fold lower than that of p55-PEG and a faster off rate. Native and p75-Fc pass TNF-alpha to membrane receptors more readily than does native or p55-PEG, which may partly explain the increased mortality in patients with sepsis who are treated with p75-Fc.
引用
收藏
页码:1722 / 1730
页数:9
相关论文
共 39 条
  • [1] p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial
    Abraham, E
    Glauser, MP
    Butler, T
    Garbino, J
    Gelmont, D
    Laterre, PF
    Kudsk, K
    Bruining, HA
    Otto, C
    Tobin, E
    Zwingelstein, C
    Lesslauer, W
    Leighton, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19): : 1531 - 1538
  • [2] STABILIZATION OF THE BIOACTIVITY OF TUMOR-NECROSIS-FACTOR BY ITS SOLUBLE RECEPTORS
    ADERKA, D
    ENGELMANN, H
    MAOR, Y
    BRAKEBUSCH, C
    WALLACH, D
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) : 323 - 329
  • [3] BELIZARIO JE, 1991, CANCER RES, V51, P2379
  • [4] BORTH W, 1990, BLOOD, V75, P2388
  • [5] Ligand passing by the p75 tumour necrosis factor receptor enhances HIV-1 activation
    Butera, ST
    Roberts, BD
    Folks, TM
    [J]. CYTOKINE, 1996, 8 (10) : 745 - 750
  • [6] Anti-interleukin-8 monoclonal antibody reduces free radical production and improves hemodynamics and survival rate in endotoxic shock in rabbits
    Carvalho, GL
    Wakabayashi, G
    Shimazu, M
    Karahashi, T
    Yoshida, M
    Yamamoto, S
    Matsushima, K
    Mukaida, N
    Clark, BD
    Takabayashi, T
    Brandt, CT
    Kitajima, M
    [J]. SURGERY, 1997, 122 (01) : 60 - 68
  • [7] CHERNOFF AE, 1995, J IMMUNOL, V154, P5492
  • [8] DeLa Cadena RA, 1998, THROMB HAEMOSTASIS, V80, P114
  • [9] Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma
    DuBois, JS
    Trehu, EG
    Mier, JW
    Shapiro, L
    Epstein, M
    Klempner, M
    Dinarello, C
    Kappler, K
    Ronayne, L
    Rand, W
    Atkins, MB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 1052 - 1062
  • [10] Edwards CK, 1999, ANN RHEUM DIS, V58, P73